TNF and Cowden disease: Throughout the years, several molecules with different mechanisms of action have been approved for CD treatment: monoclonal antibodies acting against IL 12–23 (ustekinumab) and anti a4b7 blockers (vedolizumab)) have been added to the anti-tumor necrosis factor α (TNFα) agents [2].